-- Merger to Create a Sustainable Biotechnology Company: Brings Together Significant Product Assets, Unique Discovery Capabilities and Financial Resources - CAMBRIDGE, Mass. & VANCOUVER, British ...

REDWOOD CITY, Calif., Oct. 7, 2025 /PRNewswire/ -- Precision NeuroMed (PNM), a clinical-stage biotechnology company pioneering advanced drug delivery technologies for central nervous system (CNS) ...

MUNICH & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Brainlab SE (Brainlab), a digital medical technology company automating and optimizing clinical workflows using artificial intelligence and ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--CombinatoRx, Incorporated (NASDAQ: CRXX) and Neuromed Pharmaceuticals Inc. announced today that they have merged. This merger brings together the product assets and ...

An exclusive out-licensing deal could be worth up to $475 million to Neuromed Pharmaceuticals Ltd., which entered an agreement with Merck & Co. Inc. on N-type calcium channel blockers for pain and ...

Vancouver's Neuromed Pharmaceuticals Ltd. has signed a $30 million licensing deal for the exclusive U.S. rights to market a chronic pain drug developed by ALZA Corp., a California-based subsidiary of ...

-- Merger to Create a Sustainable Biotechnology Company: Brings Together Significant Product Assets, Unique Discovery Capabilities and Financial Resources - CAMBRIDGE, Mass. & VANCOUVER, British ...

Brainlab SE (Brainlab), a digital medical technology company automating and optimizing clinical workflows using artificial intelligence and sophisticated software algorithms, and Precision NeuroMed ...

Under the terms of the merger agreement, CombinatoRx is expected to issue approximately 36 million new shares of its common stock to Neuromed stockholders with each party owning approximately 50% of ...

The collaboration aims to standardize and scale the delivery planning of targeted therapies directly into brain tissue, overcoming long-standing limitations imposed by the blood-brain barrier, which ...